Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Relationships and Activities. The Council of Experts was supported by AstraZeneca.
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-06-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3919 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341558635102208 |
|---|---|
| author | S. N. Tereshchenko M. V. Shestakova F. T. Ageev G. R. Galstyan A. S. Galyavich M. G. Glezer I. V. Zhirov Yu. A. Karpov Zh. D. Kobalava S. T. Matskeplishvili |
| author_facet | S. N. Tereshchenko M. V. Shestakova F. T. Ageev G. R. Galstyan A. S. Galyavich M. G. Glezer I. V. Zhirov Yu. A. Karpov Zh. D. Kobalava S. T. Matskeplishvili |
| author_sort | S. N. Tereshchenko |
| collection | DOAJ |
| description | Relationships and Activities. The Council of Experts was supported by AstraZeneca. |
| format | Article |
| id | doaj-art-efcda189d1b94fcebbfc56fead0270a5 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2020-06-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-efcda189d1b94fcebbfc56fead0270a52025-08-20T03:43:36Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-06-0125510.15829/1560-4071-2020-39192945Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statementS. N. Tereshchenko0M. V. Shestakova1F. T. Ageev2G. R. Galstyan3A. S. Galyavich4M. G. Glezer5I. V. Zhirov6Yu. A. Karpov7Zh. D. Kobalava8S. T. Matskeplishvili9National Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical EducationNational Medical Research Center for EndocrinologyNational Medical Research Center of CardiologyNational Medical Research Center for EndocrinologyKazan State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityNational Medical Research Center of Cardiology; Russian Academy of Postgraduate Medical EducationNational Medical Research Center of CardiologyPeoples’ Friendship University of RussiaMedical Research and Educational Center. Moscow State UniversityRelationships and Activities. The Council of Experts was supported by AstraZeneca.https://russjcardiol.elpub.ru/jour/article/view/3919heart failure with reduced ejection fractiondapa-hf trialdapagliflozin |
| spellingShingle | S. N. Tereshchenko M. V. Shestakova F. T. Ageev G. R. Galstyan A. S. Galyavich M. G. Glezer I. V. Zhirov Yu. A. Karpov Zh. D. Kobalava S. T. Matskeplishvili Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement Российский кардиологический журнал heart failure with reduced ejection fraction dapa-hf trial dapagliflozin |
| title | Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement |
| title_full | Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement |
| title_fullStr | Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement |
| title_full_unstemmed | Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement |
| title_short | Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement |
| title_sort | rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction expert consensus statement |
| topic | heart failure with reduced ejection fraction dapa-hf trial dapagliflozin |
| url | https://russjcardiol.elpub.ru/jour/article/view/3919 |
| work_keys_str_mv | AT sntereshchenko rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT mvshestakova rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT ftageev rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT grgalstyan rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT asgalyavich rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT mgglezer rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT ivzhirov rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT yuakarpov rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT zhdkobalava rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement AT stmatskeplishvili rationalefordapagliflozinadministrationforthepreventionofadverseoutcomesinpatientswithheartfailurewithreducedejectionfractionexpertconsensusstatement |